Mitochondrial Complex I Activity is Conditioned by Supercomplex I-III2-IV Assembly in Brain Cells: Relevance for Parkinson's Disease

被引:16
|
作者
Lopez-Fabuel, Irene [1 ,2 ]
Resch-Beusher, Monica [1 ,2 ]
Carabias-Carrasco, Monica [1 ,2 ]
Almeida, Angeles [1 ,2 ]
Bolanos, Juan P. [1 ,2 ]
机构
[1] Univ Salamanca, CSIC, Inst Funct Biol & Genom IBFG, Zacarias Gonzalez 2, Salamanca 37007, Spain
[2] Univ Hosp Salamanca, Inst Biomed Res Salamanca IBSAL, Salamanca 37007, Spain
关键词
Neurons; Astrocytes; Bioenergetics; Parkinson's disease; Mitochondria; Complexes; RESPIRATORY-CHAIN; DEFICIENCY; ASTROCYTES; CRISTAE; NEURONS; FLUX; RAT;
D O I
10.1007/s11064-017-2191-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The assembly of complex I (CI) with complexes III (CIII) and IV (CIV) of the mitochondrial respiratory chain (MRC) to configure I-III- or I-III-IV-containing supercomplexes (SCs) regulates mitochondrial energy efficiency and reactive oxygen species (mROS) production. However, whether the occurrence of SCs impacts on CI specific activity remains unknown to our knowledge. To investigate this issue, here we determined CI activity in primary neurons and astrocytes, cultured under identical antioxidants-free medium, from two mouse strains (C57Bl/6 and CBA) and Wistar rat, i.e. three rodent species with or without the ability to assemble CIV into SCs. We found that CI activity was 6- or 1.8-fold higher in astrocytes than in neurons, respectively, from rat or CBA mouse, which can form I-III2-IV SC; however, CI activity was similar in the cells from C57Bl/6 mouse, which does not form I-III2-IV SC. Interestingly, CII-III activity, which was comparable in neurons and astrocytes from mice, was about 50% lower in astrocytes when compared with neurons from rat, a difference that was abolished by antioxidants- or serum-containing media. CIV and citrate synthase activities were similar under all conditions studied. Interestingly, in rat astrocytes, CI abundance in I-III2-IV SC was negligible when compared with its abundance in I-III-containing SCs. Thus, CIV-containing SCs formation may determine CI specific activity in astrocytes, which is important to understand the mechanism for CI deficiency observed in Parkinson's disease.
引用
收藏
页码:1676 / 1682
页数:7
相关论文
共 43 条
  • [21] Mitochondrial Complex I Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease
    Milanese, Chiara
    Tapias, Victor
    Gabriels, Sylvia
    Cerri, Silvia
    Levandis, Giovanna
    Blandini, Fabio
    Tresini, Maria
    Shiva, Sruti
    Greenamyre, John Timothy
    Gladwin, Mark T.
    Mastroberardino, Pier G.
    ANTIOXIDANTS & REDOX SIGNALING, 2018, 28 (01) : 44 - 61
  • [22] Up-regulation of γ-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity:: Implications for Parkinson's disease
    Chinta, Shankar J.
    Kumar, Jyothi M.
    Zhang, Hongqiao
    Forman, Henry Jay
    Andersen, Julie K.
    FREE RADICAL BIOLOGY AND MEDICINE, 2006, 40 (09) : 1557 - 1563
  • [23] Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease
    Holper, L.
    Ben-Shachar, D.
    Mann, J. J.
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (05) : 837 - 849
  • [24] Mitochondrial E3 ligase TRIM71 affects mitochondrial complex assembly and sensitizes dopaminergic neuronal cells to apoptosis in Parkinson's Disease (PD)
    Goyani, Shanikumar
    Shukla, Shatakshi
    Mane, Minal
    Saranga, M. V.
    Chandak, Nisha
    Shinde, Anjali
    Currim, Fatema
    Singh, Jyoti
    Singh, Rajesh
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2024, 177
  • [25] Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models
    Xiong, Nian
    Long, Xi
    Xiong, Jing
    Jia, Min
    Chen, Chunnuan
    Huang, Jinsha
    Ghoorah, Devina
    Kong, Xiangquan
    Lin, Zhicheng
    Wang, Tao
    CRITICAL REVIEWS IN TOXICOLOGY, 2012, 42 (07) : 613 - 632
  • [26] Dysfunction of mitochondrial complex I and the proteasome:: interactions between two biochemical deficits in a cellular model of Parkinson's disease
    Höglinger, GU
    Carrard, G
    Michel, PP
    Medja, F
    Lombès, A
    Ruberg, M
    Friguet, B
    Hirsch, EC
    JOURNAL OF NEUROCHEMISTRY, 2003, 86 (05) : 1297 - 1307
  • [27] Is there a special relationship between complex I activity and nigral neuronal loss in Parkinson's disease? A critical reappraisal
    Subrahmanian, Nitya
    LaVoie, Matthew J.
    BRAIN RESEARCH, 2021, 1767
  • [28] Mitochondrial Complex I Inhibition in Dopaminergic Neurons Causes Altered Protein Profile and Protein Oxidation: Implications for Parkinson's disease
    Chithra, Yogeshachar
    Dey, Gourav
    Ghose, Vivek
    Chandramohan, Vivek
    Gowthami, Niya
    Vasudev, V.
    Bharath, M. M. Srinivas
    NEUROCHEMICAL RESEARCH, 2023, 48 (08) : 2360 - 2389
  • [29] Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease
    Hsu, M
    Srinivas, B
    Kumar, J
    Subramanian, R
    Andersen, J
    JOURNAL OF NEUROCHEMISTRY, 2005, 92 (05) : 1091 - 1103
  • [30] N-Acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice:: implications for treatment of Parkinson's disease
    Banaclocha, MM
    BRAIN RESEARCH, 2000, 859 (01) : 173 - 175